Neumora Therapeutics, an early-stage neuroscience drug development company, focuses on three key areas, alzheimer's agitation, schizophrenia and obesity. The companies three lead candidates, will have early stage clinical trial read-outs, by the end of 2026.
Financial Statistics:
- $147 million cash
- 180 million diluted shares outstanding
- 270 million market cap
- 180 million diluted shares outstanding
- 270 million market cap
Intellectual Property:
- NMRA - 511 Alzheimer's Agitation, Expected to expire into 2042
- NMRA - 898 Schizophrenia, Expected to expire in 2044
- NMRA - 215 Obesity, Expected to expire in 2043
Timeline Catalyst:
- NMRA-511: Multiple ascending dose completion in the fourth quarter 2026
- NMRA-898: Phase 1 data 2H of 2026
- NMRA-215: Start clinical trials by end of 2026
Neumora is a clinical stage biotech company focused on three areas of unmet need. The stock is priced at $1.51 per share (penny stock). There are many risks to investing in this company.
Disclaimer: This stock, or any other stock referenced on this site, is for purely educational purposes. Consult with your investment advisor professional, prior to buying stocks, precious metals, or commodity's.
